Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Relapsing Remitting Multiple Sclerosis Males or females, aged between 18 and 50 years. 2. Diagnosis of RR-MS according to McDonald 2010 diagnostic with a prior brain MRI that demonstrates lesions consistent with RRMS, both within the past year. 3. No evidence of relapse during the 60 days prior to enrollment. 4. EDSS score of 0-5 at screening. 5. Women of childbearing potential who have a negative pregnancy test (serum HCG) at screening. 6. Men or women of reproductive potential who commit to use adequate contraception during the study and for 1 month following the last day of treatment. 7. Subjects must be capable of understanding the purpose and risks of the study and provide written, informed consent  Diagnosis of Secondary Progressive MS, Primary Progressive MS or Progressive Relapsing MS. 2. Normal baseline brain MRI. 3. History of any clinically significant autoimmune disease: inflammatory bowel disease, diabetes, lupus or severe asthma. 4. Current or prior malignancies (excluding non-melanoma skin carcinoma or in situ carcinoma of the cervix that has been adequately treated.) 5. Significant organ dysfunction, including cardiac, renal (eGFR ≤ 60 ml/min.), liver, central nervous system, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine ≥ 1.6 mg/dL; ALT or AST ≥ 1.5x the upper limit of normal), history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to enrollment. 6. Steroid therapy within 60 days prior to enrollment, with the exception of corticosteroids or ACTH for relapse treatment during the course of the study. 7. Known allergy to Gadolinium-DTPA 8. Therapy with any immunomodulatory drugs within 3 months prior to enrollment, including but not limited to interferons, glatiramir acetate, BG-12, teriflunomide, laquinimod and IV immunoglobulin. 9. Treatment at any time with immunosuppressive drugs such as cladribine, total lymphoid irradiation, monoclonal antibody treatment, mitoxantrone, Tysabri, fingolimod, cytoxan, methotrexate. 10. Participation in any investigational therapy within one year prior to enrollment, unless given approval by PI. 11. Known or suspected current or past alcohol or drug abuse within one year prior to enrollment. 12. Any medical, psychiatric or other condition that could result in a subject not being able to comply with protocol requirements